Scott Delacroix

Clinical trials

• Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

  Principal investigator · Recruiting · Phase 3

  NRG Oncology

  2025–2035
• A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

  Site PI · Recruiting · Phase 3

  National Cancer Institute (NCI)

  2025–2030
• Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy

  Site PI · Recruiting · Phase 3

  Alliance for Clinical Trials in Oncology

  2025–2028
• Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

  Site PI · Recruiting · Phase 2

  National Cancer Institute (NCI)

  2025–2032